RPG Life Sciences Ltd - 532983 - Announcement under Regulation 30 (LODR)-Newspaper Publication
In terms of the Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith a copy of the newspaper publications with respect to Audited Financial Results for the quarter and year ended March 31, 2021. Kindly take this information on record. RPG Life Sciences Ltd - 532983 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Please find enclosed herewith a copy of press release with respect to Audited Financial Results of the Company for the financial year ended March 31, 2021. Kindly take the above on record. RPG Life Sciences Ltd - 532983 - Corporate Action-Board approves Dividend
Recommended equity dividend of Rs. 7.20 per share of Rs. 8/- each (90%) for the financial year ended March 31, 2021, which will be paid to the shareholders within 30 days of declaration of the same at the ensuing Annual General Meeting RPG Life Sciences Ltd - 532983 - Audited Financial Results For The Quarter And Year Ended March 31, 2021
Audited Financial Results of RPG Life Sciences Limited, for the quarter and year ended March 31, 2021, approved and taken on record by the Board of Directors of RPG Life Sciences Limited at its meeting held on April 30, 2021 along with Auditors Report thereon with unmodified opinion. The Board meeting commenced at 3.00 p.m. and concluded at 6.00 p.m. RPG Life Sciences Ltd - 532983 - Outcome Of The Board Meeting Held On April 30, 2021
Outcome of the meeting of the Board of Directors of RPG Life Sciences Limited held on April 30, 2021, in terms of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Board meeting commenced at 3.00 p.m. and concluded at 6.00 p.m. RPG LIFE SCIENCES LTD. - 532983 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayRPG LIFE SCIENCES LTD. 2CINL24232MH2007PLC169354 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Rajesh Shirambekar Designation: Company Secretary & Compliance Officer EmailId: [email protected] Name of the Chief Financial Officer: Vishal Shah Designation: Chief Financial Officer EmailId: [email protected] Date: 27/04/2021 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. RPG LIFE SCIENCES LTD. - 532983 - Announcement under Regulation 30 (LODR)-Newspaper Publication
In terms of the Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith a copy of the newspaper notice published to give intimation of the meeting of Board of Directors of the Company scheduled to be held on April 30, 2021, inter alia, to consider and approve the audited financial results for the quarter and year ended March 31, 2021 and to recommend dividend, if any, for the financial year March 31, 2021. Kindly take this information on record. RPG Life Sciences Ltd - 532983 - Board Meeting Intimation for Approval Of Audited Financial Results For The Quarter And Year Ended March 31, 2021.
RPG LIFE SCIENCES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/04/2021 ,inter alia, to consider and approve Pursuant to the provisions of Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations, 2015'), this is to inform you that a meeting of the Board of Directors of the Company is scheduled on Friday, April 30, 2021, inter-alia, to consider and approve the Audited Financial Results for the quarter and year ended March 31, 2021. Further, pursuant to the 'Code of Fair Disclosure, Internal Procedures and Conduct for Regulating, Monitoring and Reporting of Trading by Insiders' of the Company and the SEBI (Prohibition of Insider Trading) Regulations, 2015, the Trading Window for dealing in Securities of the Company by Designated Persons and their immediate relatives, is closed from April 1, 2021 and will continue to remain closed till 48 hours after the results are made public on April 30, 2021. Kindly take this information on record. RPG LIFE SCIENCES LTD. - 532983 - Clarification On Increase In Volume
With reference to your above referred email dated April 22, 2021 seeking clarification on significant increase in the volume of security across Exchanges in the recent past, we wish to inform you that there are no events, information, announcements etc. that have a bearing on the operations/performance of the Company which includes price sensitive information, which is required to be disclosed to the stock exchanges pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Hence, we are unable to comment on the significant increase in the volume of Company's security across Exchanges, in the recent past. Further, we would like to reiterate that, as in the past, the Company would continue to inform stock exchanges regularly about any price sensitive information and to make it available on the website of the Company before the same is made public. Kindly request you to take the same on record.